COMMUNIQUÉS West-GlobeNewswire

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
18/05/2026
Offering oversubscribed through full exercise of underwriters’ option, supported by strong investor demand Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds expected to [...]
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
18/05/2026
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Novo Nordisk A/S - share repurchase programme
18/05/2026
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and [...]
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18/05/2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics [...]
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
18/05/2026
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling [...]
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
18/05/2026
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage [...]
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
18/05/2026
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU [...]
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
18/05/2026
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to [...]
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
18/05/2026
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved [...]
Parexel Launches ParexelAI™, Delivering AI Innovation to Accelerate Clinical Development
18/05/2026
Innovative, proprietary suite of artificial intelligence services and capabilities deliver proven speed, quality and efficiency results for sponsors and patients RALEIGH, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Parexel, [...]
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
18/05/2026
WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced [...]
Red Ribbon Recovery Indiana reports strong patient outcomes in first year of operation
18/05/2026
New Indiana rehab reports 88% sobriety at 30 days — and 70% at six months Greenwood, Indiana, May 18, 2026 (GLOBE NEWSWIRE) -- Red Ribbon Recovery Indiana, which marks its first year of operation this June, is releasing [...]
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
18/05/2026
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded [...]
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
18/05/2026
Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans [...]
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
18/05/2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata [...]
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
18/05/2026
ORANGE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, Florida, on [...]
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
18/05/2026
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
18/05/2026
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000 [...]
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05/2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]

Pages